Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 99

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 99
---
 with chronic kidney disease. Prevention of Post Surgical Infection There are no approved therapies currently available for the prevention of infection outside of pre- and post -surgicaladministration of antibiotics and commonly recommended procedures for the preventing the transmission of bacteria including hand washing, mask wearing, and cleaning the surgical site pre- and post -surgery. In the case of antibiotic pretreatment, the typical course of treatment may require an initial empiric broad -spectrumantibiotic, later targeted to an organism if detected, with consideration for the presence of multidrug resistant pathogens, specifically MRSA. Antibiotic resistance has become a major consideration in the need for pretreatment of yet -to -bediagnosed infections, as the number of antibiotic resistant strains have increased, and the over prescription of antibiotics further contributes to resistance. Prevention of Post Burn Infection For smaller burn wounds (e.g., those not requiring hospitalization), the wound can be cleaned out with soap and water, significantly reducing the likelihood of any significant infection. The current standard of care for severe burn incorporates aggressive fluid resuscitation, alleviation of the hypermetabolic response, adequate and effective surgical grafting and coverage of burn wounds, pulmonary hygiene and ventilation, nutritional support, and infection control measures. It is common practice to treat all burn wounds with topical antimicrobial ointment to reduce infection. While the use of topical antimicrobials is common practice for burn wounds, it is not clear if the topical antimicrobials prevent infection or simply select out more resistant organisms. More importantly, multiple studies have shown that systemic administration of antibiotics doesselect out resistant organisms. As such, it is recommended that prophylactic systemic antibiotics should be avoided in the treatment of burn patients (Greenhalgh 2024). The current standard of care for patients with severe burns requiring hospitalization still results in a significant annual number of burn -relateddeaths, the majority of which are due to invasive infection. This, in combination with the number of antibiotic -resistantstrains on the rise, creates an urgent need for new, more effective therapies such as Gemini to prevent infection in severe burn patients 61 REVELATION’S PROGRAMS Gemini Platform Our current therapeutic candidates are all based on Gemini, our proprietary formulation of PHAD ®, a synthetic version of MPLA, that is known to stimulate the innate immune response via TLR4. The innate immune system is our first line of defense against stress such as trauma, infection and acute and chronic disorders. The innate immune system responds to stress (e.g